At first glance, Merck & Co., Inc.’s $11.5bn acquisition of Acceleron Pharma, Inc. with a commercial drug and a late-stage candidate seen as a potential blockbuster seems like a good deal for a company looking to diversify its revenue. However, Acceleron recognizes only a portion of sales from its sole commercial product Reblozyl (luspatercept) from partner Bristol Myers Squibb Company and will have to pay BMS royalties on sales of the Phase III pulmonary arterial hypertension (PAH) drug sotatercept.
Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
Deal Expands Existing Cardiovascular Portfolio
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.